MARC HOROWITZ to Adolescent
This is a "connection" page, showing publications MARC HOROWITZ has written about Adolescent.
Connection Strength
0.101
-
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996 Aug 15; 78(4):901-11.
Score: 0.010
-
Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996 Mar; 14(3):901-10.
Score: 0.009
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.
Score: 0.009
-
Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993 Oct; 11(10):1911-8.
Score: 0.008
-
Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):389-95.
Score: 0.007
-
Feasibility and efficacy of preirradiation chemotherapy for pediatric brain tumors. Neurosurgery. 1988 Apr; 22(4):687-90.
Score: 0.005
-
Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer. 1987 Feb 01; 59(3):396-402.
Score: 0.005
-
Therapy for childhood soft-tissue sarcomas other than rhabdomyosarcoma: a review of 62 cases treated at a single institution. J Clin Oncol. 1986 Apr; 4(4):559-64.
Score: 0.005
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.005
-
Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986; 18(1):69-73.
Score: 0.005
-
Reoperative pulmonary metastasectomy for sarcomatous pediatric histologies. Ann Thorac Surg. 1998 Sep; 66(3):908-12; discussion 913.
Score: 0.003
-
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996 Oct; 14(10):2818-25.
Score: 0.002
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.002
-
Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg. 1995 Jun; 59(6):1385-9; discussion 1390.
Score: 0.002
-
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
Score: 0.002
-
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 01; 84(7):2221-8.
Score: 0.002
-
Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):735-45.
Score: 0.002
-
A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer. 1993 Jul 01; 72(1):271-5.
Score: 0.002
-
Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer. 1992 Nov; 5(4):299-310.
Score: 0.002
-
Neuraxis dissemination in pediatric brain tumors. Response to preirradiation chemotherapy. Cancer. 1992 Feb 15; 69(4):1061-6.
Score: 0.002
-
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs. 1990 May; 8(2):181-2.
Score: 0.002
-
Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiother Oncol. 1989 Nov; 16(3):189-201.
Score: 0.002
-
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin Oncol. 1989 Feb; 16(1 Suppl 3):51-5.
Score: 0.001
-
The impact of delayed surgery on radiotherapy dose and local control of rhabdomyosarcoma. Arch Surg. 1987 Dec; 122(12):1451-4.
Score: 0.001
-
Challenges in the treatment of childhood fibromatosis. Arch Surg. 1987 Nov; 122(11):1296-8.
Score: 0.001
-
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 1987 Mar 01; 47(5):1457-60.
Score: 0.001
-
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep. 1987 Feb; 71(2):127-30.
Score: 0.001
-
Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987 Feb; 71(2):131-5.
Score: 0.001
-
Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer. 1986 Dec 15; 58(12):2617-21.
Score: 0.001